Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Natalizumab, When Added to Avonex® (Interferon Beta-1a), in Subjects With Relapsing-Remitting Multiple Sclerosis
Brief Summary: The purpose of this study is to determine if natalizumab in combination with AVONEX is safe and effective in delaying progression of individuals diagnosed with relapsing remitting Multiple Sclerosis (MS).


Options:
A: Arm Label: Group 1: DAC HYP 150 mg; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process) | Arm Label: Group 1: DAC HYP 300 mg; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process) | Arm Label: Group 2: Washout then DAC HYP 150 mg; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process), Drug: Placebo | Arm Label: Group 2: DAC HYP 150 mg; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process) | Arm Label: Group 3: Washout then DAC HYP 300 mg; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process), Drug: Placebo | Arm Label: Group 3: DAC HYP 300 mg; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process) | Intervention Type: BIOLOGICAL; Name: BIIB019 (Daclizumab High Yield Process); Assigned to Arm(s): Group 1: DAC HYP 150 mg, Group 1: DAC HYP 300 mg, Group 2: DAC HYP 150 mg, Group 2: Washout then DAC HYP 150 mg, Group 3: DAC HYP 300 mg, Group 3: Washout then DAC HYP 300 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 2: Washout then DAC HYP 150 mg, Group 3: Washout then DAC HYP 300 mg
B: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: Natalizumab | Arm Label: Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Natalizumab; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 2
C: Arm Label: Natalizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Natalizumab | Arm Label: Interferon-beta-1b; Type: EXPERIMENTAL; Interventions: Drug: interferon beta-1b | Intervention Type: DRUG; Name: interferon beta-1b; Assigned to Arm(s): Interferon-beta-1b | Intervention Type: DRUG; Name: Natalizumab; Assigned to Arm(s): Natalizumab
D: Arm Label: Daclizumab High Yield Process 150 mg SC; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process), Drug: Interferon beta-1a Placebo | Arm Label: IFN β-1a 30 µg IM; Type: ACTIVE_COMPARATOR; Interventions: Biological: Interferon beta-1a, Drug: Daclizumab High Yield Process Placebo | Intervention Type: BIOLOGICAL; Name: BIIB019 (Daclizumab High Yield Process); Assigned to Arm(s): Daclizumab High Yield Process 150 mg SC | Intervention Type: DRUG; Name: Interferon beta-1a Placebo; Assigned to Arm(s): Daclizumab High Yield Process 150 mg SC | Intervention Type: BIOLOGICAL; Name: Interferon beta-1a; Assigned to Arm(s): IFN β-1a 30 µg IM | Intervention Type: DRUG; Name: Daclizumab High Yield Process Placebo; Assigned to Arm(s): IFN β-1a 30 µg IM

Answer: B